North America Semaglutide Market Size & Outlook, 2024-2035
Related Markets
North America semaglutide market highlights
- The North America semaglutide market generated a revenue of USD 21,137.4 million in 2024.
- The market is expected to grow at a CAGR of 9.7% from 2025 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2024.
- Ozempic (semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2035.
North America data book summary
| Market revenue in 2024 | USD 21,137.4 million |
| Market revenue in 2035 | USD 62,629.0 million |
| Growth rate | 9.7% (CAGR from 2025 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Ozempic (semaglutide) |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
Other key industry trends
- In terms of revenue, North America region accounted for 74.3% of the global semaglutide market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2035.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,055.5 million by 2035.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Semaglutide Market Scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America semaglutide market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 71.15% in 2024. Horizon Databook has segmented the North America semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
The North America semaglutide market holds a leading position in 2024, accounting for 74.35% of the global share, driven by high obesity and diabetes prevalence, strong healthcare infrastructure, and widespread adoption of GLP-1 receptor agonists like Ozempic and Wegovy.
The region benefits from favorable reimbursement policies, increasing weight management awareness, and rising prescriptions for off-label use. The U.S. dominates due to robust pharmaceutical regulations, active patient engagement, and significant investments in obesity therapeutics.
Additionally, market growth is fueled by ongoing clinical advancements, including oral semaglutide formulations. With continuous regulatory oversight and expanding treatment accessibility, North America remains the largest market for semaglutide-based therapies.
Reasons to subscribe to North America semaglutide market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America semaglutide market databook
-
Our clientele includes a mix of semaglutide market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America semaglutide market , including forecasts for subscribers. This continent databook contains high-level insights into North America semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
Partial client list
North America semaglutide market size, by country, 2018-2035 (US$M)
North America Semaglutide Market Outlook Share, 2024 & 2035 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
